MA45187A - Combinaisons pharmaceutiques - Google Patents

Combinaisons pharmaceutiques

Info

Publication number
MA45187A
MA45187A MA045187A MA45187A MA45187A MA 45187 A MA45187 A MA 45187A MA 045187 A MA045187 A MA 045187A MA 45187 A MA45187 A MA 45187A MA 45187 A MA45187 A MA 45187A
Authority
MA
Morocco
Prior art keywords
pharmaceutical combinations
pharmaceutical
combinations
Prior art date
Application number
MA045187A
Other languages
English (en)
Inventor
Zhu Alexander Cao
Giordano Caponigro
Original Assignee
Zhu Alexander Cao
Giordano Caponigro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60477982&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA45187(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zhu Alexander Cao, Giordano Caponigro filed Critical Zhu Alexander Cao
Publication of MA45187A publication Critical patent/MA45187A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
MA045187A 2016-06-03 2017-06-02 Combinaisons pharmaceutiques MA45187A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662345389P 2016-06-03 2016-06-03

Publications (1)

Publication Number Publication Date
MA45187A true MA45187A (fr) 2019-04-10

Family

ID=60477982

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045187A MA45187A (fr) 2016-06-03 2017-06-02 Combinaisons pharmaceutiques

Country Status (26)

Country Link
US (3) US10485788B2 (fr)
EP (1) EP3463345B1 (fr)
JP (2) JP6805336B2 (fr)
KR (1) KR102439911B1 (fr)
CN (1) CN109890386B (fr)
AU (1) AU2017275650B2 (fr)
BR (1) BR112018074941A2 (fr)
CA (1) CA3026361A1 (fr)
CL (1) CL2018003421A1 (fr)
CO (1) CO2019000010A2 (fr)
CR (1) CR20190002A (fr)
DK (1) DK3463345T3 (fr)
FI (1) FI3463345T3 (fr)
HU (1) HUE060653T2 (fr)
IL (1) IL263431A (fr)
MA (1) MA45187A (fr)
MX (1) MX2018014973A (fr)
PH (1) PH12018502549A1 (fr)
PL (1) PL3463345T3 (fr)
PT (1) PT3463345T (fr)
RU (1) RU2759669C2 (fr)
SG (1) SG11201810793XA (fr)
SI (1) SI3463345T1 (fr)
UA (1) UA125436C2 (fr)
WO (1) WO2017210538A1 (fr)
ZA (1) ZA201900019B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6805336B2 (ja) 2016-06-03 2020-12-23 アレイ バイオファーマ、インコーポレイテッド 薬学的組み合わせ
US10973829B2 (en) 2016-09-19 2021-04-13 Novartis Ag Therapeutic uses of a C-RAF inhibitor
US11266653B2 (en) 2017-05-02 2022-03-08 Novartis Ag Combination therapy
AU2020363843A1 (en) * 2019-10-11 2022-03-24 F. Hoffmann-La Roche Ag Drug dosage determination devices and methods
WO2021163072A1 (fr) * 2020-02-10 2021-08-19 Cedars-Sinai Medical Center Méthode de traitement du cancer du pancréas
JP7288220B2 (ja) 2021-03-29 2023-06-07 ダイキン工業株式会社 モータ、送風装置、および冷凍装置
WO2023230554A1 (fr) 2022-05-25 2023-11-30 Pfizer Inc. Combinaison d'un inhibiteur de braf, d'un inhibiteur d'egfr et d'un antagoniste de pd-1 pour le traitement du cancer colorectal msi-h/dmmr, avec mutation v600e de braf
WO2024126660A1 (fr) * 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Polythérapie pour le traitement du cancer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
WO1996040210A1 (fr) 1995-06-07 1996-12-19 Imclone Systems Incorporated Anticorps et fragments d'anticorps inhibant la croissance des tumeurs
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
DE60330227D1 (de) 2002-03-13 2010-01-07 Array Biopharma Inc N3-alkylierte benzimidazol-derivate als mek-hemmer
WO2008120004A1 (fr) 2007-04-02 2008-10-09 Astrazeneca Ab Combinaison d'un inhibiteur de mek et d'un inhibiteur de b-raf pour le traitement du cancer
WO2010010154A1 (fr) 2008-07-24 2010-01-28 Nerviano Medical Sciences S.R.L. 3,4-diarylpyrazoles utilisés comme inhibiteurs de protéine kinase
JP5527878B2 (ja) * 2009-07-30 2014-06-25 トムソン ライセンシング 表示装置及び音声出力装置
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
WO2012170715A1 (fr) * 2011-06-07 2012-12-13 Caris Mpi, Inc. Profilage moléculaire pour le cancer
WO2013070996A1 (fr) 2011-11-11 2013-05-16 Novartis Ag Procédé de traitement d'une maladie proliférative
ES2695099T3 (es) 2011-11-23 2019-01-02 Array Biopharma Inc Formulaciones farmacéuticas
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
KR102112885B1 (ko) * 2012-08-07 2020-05-19 노파르티스 아게 B-raf 억제제, egfr 억제제 및 임의로 pi3k-알파 억제제를 포함하는 제약 조합물
HUE065433T2 (hu) * 2012-10-19 2024-05-28 Array Biopharma Inc MEK inhibitort tartalmazó kompozíció
WO2014066606A2 (fr) * 2012-10-25 2014-05-01 Glaxosmithkline Llc Combinaison
PT2976106T (pt) 2013-03-21 2021-05-26 Array Biopharma Inc Terapia de combinação que compreende um inibidor de b-raf e um segundo inibidor
CN105392763A (zh) 2013-07-18 2016-03-09 株式会社大赛璐 氧化物的制造方法
US20150087279A1 (en) * 2013-09-20 2015-03-26 Better Mousetrap, LLC Mobile accident processing system and method
WO2015087279A1 (fr) * 2013-12-12 2015-06-18 Glaxosmithkline Intellectual Property (No.2) Limited Combinaisons de tramétinib, panitumumab et dabrafénib pour le traitement du cancer
CN105566225A (zh) * 2015-02-16 2016-05-11 苏州晶云药物科技有限公司 一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法
EP3279201B1 (fr) * 2015-04-01 2019-10-23 Crystal Pharmatech Co., Ltd. Inhibiteur de cdk, cristal eutectique d'inhibiteur de mek, et leur procédé de préparation
US20170027951A1 (en) 2015-07-27 2017-02-02 Southern Research Institute Methods and compositions to treat cancers involving egfr
JP6805336B2 (ja) 2016-06-03 2020-12-23 アレイ バイオファーマ、インコーポレイテッド 薬学的組み合わせ

Also Published As

Publication number Publication date
KR102439911B1 (ko) 2022-09-05
CL2018003421A1 (es) 2019-07-19
CN109890386B (zh) 2022-05-24
AU2017275650A1 (en) 2019-01-17
EP3463345A4 (fr) 2020-02-26
IL263431A (en) 2019-01-31
CO2019000010A2 (es) 2019-05-21
FI3463345T3 (fi) 2023-01-31
RU2018146812A3 (fr) 2020-10-09
JP2019525948A (ja) 2019-09-12
MX2018014973A (es) 2019-12-18
RU2759669C2 (ru) 2021-11-16
CA3026361A1 (fr) 2017-12-07
PT3463345T (pt) 2023-01-06
US20190105303A1 (en) 2019-04-11
JP6805336B2 (ja) 2020-12-23
SG11201810793XA (en) 2018-12-28
AU2017275650B2 (en) 2023-06-01
RU2018146812A (ru) 2020-07-09
CR20190002A (es) 2019-06-10
US20200230108A1 (en) 2020-07-23
UA125436C2 (uk) 2022-03-09
PH12018502549A1 (en) 2019-04-08
EP3463345B1 (fr) 2022-11-02
PL3463345T3 (pl) 2023-02-06
BR112018074941A2 (pt) 2019-03-12
EP3463345A1 (fr) 2019-04-10
SI3463345T1 (sl) 2023-02-28
KR20190119507A (ko) 2019-10-22
CN109890386A (zh) 2019-06-14
US20230044943A1 (en) 2023-02-09
DK3463345T3 (da) 2023-01-09
WO2017210538A1 (fr) 2017-12-07
HUE060653T2 (hu) 2023-04-28
ZA201900019B (en) 2023-04-26
US10485788B2 (en) 2019-11-26
US11376239B2 (en) 2022-07-05
JP2021054832A (ja) 2021-04-08

Similar Documents

Publication Publication Date Title
DK3529248T3 (da) Farmaceutiske sammensætninger
DK3328880T3 (da) Terapeutiske midler
MA50541A (fr) Formulations pharmaceutiques
DK3188724T3 (da) Liposom-indkapslet affinitetsmedikament
MA42303A (fr) Formulations pharmaceutiques
MA45187A (fr) Combinaisons pharmaceutiques
MA46867A (fr) Formulations pharmaceutiques
DK3529240T3 (da) Farmaceutiske forbindelser
BR112017027227A2 (pt) Agente anti-câncer
DK3634377T3 (da) Farmaceutisk formulering
ES2977545T3 (es) Composición farmacéutica
MA54716A (fr) Réduction de la viscosité de formulations pharmaceutiques
DE112017003628A5 (de) Fortbewegungshilfe
DK3199161T3 (da) Farmaceutisk præparat
MA44987A (fr) Formulations de médicaments améliorées
MA49837A (fr) Compositions pharmaceutiques
DK3313370T3 (da) Oftalmologisk farmaceutisk sammensætning
DK3280447T3 (da) Farmaceutiske formuleringer
MA41850A (fr) Nouvelles utilisations pharmaceutiques
ES1150811Y (es) Torniquete sanitario
DK3601277T3 (da) Farmaceutisk formulering
DK3519025T3 (da) Indgivelsesanordning
DK3432887T3 (da) Anti-tuberkulosemiddel
DE112017002511A5 (de) Schaftfräser
DK3288967T3 (da) Farmaceutisk forbindelse